AbbVie Cuts Its Guidance on ImmunoGen Deal
Drug maker AbbVie (ABBV) is lowering its current quarter guidance because of costs related to its acquisition of ImmunoGen.
AbbVie's stock dips premarket after it lowers Q1 guidance to reflect dilutive impact of ImmunoGen deal close
AbbVie Inc.'s stock ABBV, -0.41% fell 0.5% early Monday, after the drug company lowered its first-quarter guidance to reflect the dilutive impact of its closure of the acquisition of ImmunoGen. The...
Is It Too Late to Buy These 2 Brilliant Passive Income Stocks?
The healthcare industry can be a relatively stable place to invest for generating long-term wealth. AbbVie is dealing with the blow of losing Humira patent exclusivity, but there's more behind the ...
These 17 Words From AbbVie's CEO Explain Why the Stock Is Still a Buy
AbbVie's next-gen immunology superstars are well on their way to replacing Humira. The company is also an excellent dividend stock.
How I Would Invest $1,000,000 And Live Of Dividends Forever
Reaching retirement and having enough capital to build a dividend money machine are dreams shared by many. With life expectancy on the rise, high yield alone is no longer sufficient; we need to pla...
3 Stocks Just Hit New 52-Week Highs. Should You Still Be Buying?
Investors know the phrase “let your winners run,” but it's easier said than done. The temptation to take profits off the table is often too great to ignore.
5 Dividend Aristocrats Signal Buy In February And 6 To Watch
"Dividend Aristocrats. in the S&P 500 Index… have raised their annual payouts every year for at least 25 consecutive years. "--Kiplinger.com. 67 Aristocrats, screened as of February 5, 2024 represe...
7 Dividend Stocks Worth Holding for the Long Haul
Investing in dividend stocks is generally reserved for those who prefer steady returns and low volatility over the thrill of rapid potential gains. Investors saw tech stocks explode in 2023 as arti...
This is Why AbbVie (ABBV) is a Great Dividend Stock
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes?
Abbvie: Why The 3.7% Yielder With 10% Annual Return Potential Remains One Of My Go-To Investments For Income And Growth
AbbVie has a yield of 3.7% and consistent dividend growth, making it a great investment for a wide range of investors. Despite concerns about the loss of its Humira patent, AbbVie remains in a fant...
Better Dividend Stock: Pfizer vs. AbbVie
Both Pfizer and AbbVie have been raising their dividend payments every year for more than a decade. Pfizer offers a higher dividend yield than AbbVie but it's growing at a slower pace.
3 Fabulous Dividend Stocks to Buy in February
AbbVie is a Dividend King with plenty of growth potential left. Novartis offers investors a high dividend yield and strong prospects.
AbbVie Boosts Outlook for Two Key Drugs After Beating Profit, Sales Estimates
AbbVie Inc. (ABBV) shares traded near their all-time high Friday as the pharmaceutical company posted better-than-expected results and raised its sales forecast for two of its key medicines.
AbbVie (ABBV) Q4 Earnings Beat, Raises Sales View for Key Drugs
AbbVie???s (ABBV) fourth-quarter earnings and sales beat estimates. Management hikes the 2027 forecast for new immunology drugs to more than $27 billion.
AbbVie Inc. (ABBV) Q4 2023 Earnings Call Transcript
AbbVie Inc. (ABBV) Q4 2023 Earnings Call Transcript
Related Companies